
Danish pharmaceutical company Novo Nordisk keeps powering ahead in its efforts to find the first drug in the world which can treat the serious fatty liver disease non-alcoholic steatohepatitis (NASH).
"We've seen some highly convincing data with semaglutide alone. It's close to the best we've ever seen in the area. Our data is more robust from the fact that we included more patients, and included them for longer than what we've seen in many other studies," says Novo Nordisk Executive Vice President, Development Martin Holst Lange.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app